1
Home
Companies

Clearside Biomedical

#9307

Rank

$69.54M

Marketcap

US United States

Country

Clearside Biomedical
Leadership team

Dr. George M. Lasezkay J.D., Pharm.D., Pharma.D. (Pres, CEO & Director)

Mr. Charles A. Deignan (Chief Financial Officer)

Dr. Thomas A. Ciulla M.B.A., M.D. (Chief Medical Officer & Chief Devel. Officer)

Products/ Services
Biotechnology, Health Care, Medical Device, Pharmaceutical, Therapeutics
Headquarters
Alpharetta, Georgia, United States
Established
2011
Company Registration
SEC CIK number: 0001539029
Revenue
20M - 100M
Traded as
CLSD
Social Media
URL
https://www.clearsidebio.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
History

Clearside Biomedical was founded in 2011 in Alpharetta, Georgia to develop a novel, targeted treatment approach underpinned by a proprietary technological platform and capitalizing on the latest understanding of diseases of the back of the eye. Clearside Biomedical is a publicly traded company on the NASDAQ exchange with a strong and diverse leadership team.

Mission
To deliver life-changing therapies and methods of delivering drugs to restore and preserve sight.
Vision
To combat vision loss, restoring sight and improving lives around the world.
Key Team

Ms. Jenny R. Kobin (Head of Investor Relations)

Mr. Rick McElheny (VP of Corp. Devel.)

Ms. Susan L. Coultas Ph.D. (Chief Clinical Officer)

Mr. Leslie B. Zacks (Sec.)

Recognition and Awards
Clearside Biomedical has been recognized as a Technology Pioneer of the World Economic Forum, showcasing the company's innovative approach to restoring and preserving vision.
References

https://www.investing.com/equities/clearside-biomedical-inc

https://finance.yahoo.com/quote/CLSD/profile?p=CLSD

https://www.crunchbase.com/organization/clearside-biomedical

https://companiesmarketcap.com/

https://www.clearsidebio.com

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Clearside Biomedical
Leadership team

Dr. George M. Lasezkay J.D., Pharm.D., Pharma.D. (Pres, CEO & Director)

Mr. Charles A. Deignan (Chief Financial Officer)

Dr. Thomas A. Ciulla M.B.A., M.D. (Chief Medical Officer & Chief Devel. Officer)

Products/ Services
Biotechnology, Health Care, Medical Device, Pharmaceutical, Therapeutics
Headquarters
Alpharetta, Georgia, United States
Established
2011
Company Registration
SEC CIK number: 0001539029
Revenue
20M - 100M
Traded as
CLSD
Social Media
URL
https://www.clearsidebio.com